Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Dianthus Therapeutics Inc

DNTH ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: STRONG BUY

Last Close

$115.96

▲ +5.80%

Market Cap $6.49B · Vol 263.61K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$6.49B

Mid Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

+7.28%

YoY

RSI (14)

61.50

Momentum

Beta

1.25

vs Market

52W High

$116.45

0.42% below

52W Low

$19.89

483.01% above

Volume

263.61K

Avg 261.83K

P/B

3.61

Price-to-book

ROE

N/A

Return on equity

Free Float

99.68%

Public shares

Shariah Compliance8 STANDARDS

✗ Dianthus Therapeutics Inc (DNTH) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does DNTH pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+6.46%

+14.49%

+35.88%

+144.64%

YTD

+181.39%

+472.64%

+800.31%

+12.36%

Financials & Valuation

TTM · Annual

Total Revenue	$2.04M
Net Income	$-162,337,000.00
Revenue Growth (YoY)	+294.30%
Gross Margin	100.00%
Operating Margin	-8,739.34%
Net Profit Margin	-7,973.33%
ROE	N/A
ROA · ROIC	-35.88% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	781.65
P/B	3.61
P/FCF	N/A
EPS Growth	+7.28%
Outstanding Shares	55.93M

Technical Indicators

50-Day SMA	$97.22
200-Day SMA	$70.44
RSI (14)	61.50
Beta	1.25
52-Week High	$116.45
52-Week Low	$19.89

Volume Today	263.61K
Avg Daily Volume (30D)	261.83K
Relative Volume	1.01x
Volatility (10D)	46.62
Volatility (30D)	57.41
Free Float	99.68%

Analyst Consensus

STRONG BUY

Current Price $115.96

Mean Target $135.29

52W Low$19.89 52W High$116.45

Current

Target

$19.89 $116.45

Current Analyst target

+16.67% upside potential · 14 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00FB2NQ15

ISINUS2528281080

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for the treatment of severe autoimmune diseases. The Company's lead clinical-stage candidate, claseprubart, is a monoclonal antibody that is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein (C1s) - enabling less frequent and convenient self-administered subcutaneous (S.C.) injections suitable for a pre-filled pen. It is conducting three mid- to late-stage clinical trials with claseprubart in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN). The Company's second clinical-stage candidate, DNTH212, is an investigational, extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.